Serotonergic 5-HT1A/1B Agonism for Neuroprotection
🧪 Overview
Serotonergic dysfunction precedes motor symptoms in PD; 5-HT1A/1B agonism proposed to reduce neuroinflammation. Despite high druggability, the mechanism lacks human causal validation and carries extensive clinical failure history including sarizotan, with no interventional evidence demonstrating cytokine modulation in CNS.
🧬 Mechanism
⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — SLC6A4
No curated PDB or AlphaFold mapping for SLC6A4 yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for SLC6A4 (SERT), HTR1A, HTR1B.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
▸Metadataorigin_type: debate_synthesizer
| origin_type | debate_synthesizer |
| target_gene | SLC6A4 (SERT), HTR1A, HTR1B |
| _schema_version | 1 |
| composite_score | 0.42 |